Finkelstein Thompson LLP is currently investigating possible shareholder claims arising from potential breaches of fiduciary duty by certain executives and directors of Life Sciences Research, Inc. (NYSE: LSR) in connection with the proposal by Andrew Baker, LSR's Chairman and Chief Executive Officer, to acquire all of the outstanding shares of LSR for a price of $7.50 per share pursuant to a letter dated March 3, 2009. See  http://www.indymedia.org.uk/en/2009/03/423787.html